Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Optimi HealthOPTHF 45 3-Year EBITDA Growth Rate is 36.40% as of Mar. 2026, which is 23% above its 10-year median of 29.55. GuruFocus rates OPTHF with a GF Score™ of 45/100 and a GF Value™ of $0.20. The stock has 4 warning signs investors should review. Among 811 Drug Manufacturers companies, Optimi Health ranks better than 83.35% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 36.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 6 years, the highest 3-Year average EBITDA Per Share Growth Rate of Optimi Health was 36.40% per year. The lowest was 22.70% per year. And the median was 29.55% per year.
Optimi Health (OTCPK:OPTHF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Optimi Health 3-Year EBITDA Growth Rate Related Terms
OPTHF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Optimi Health's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optimi Health 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Optimi Health's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Optimi Health's 3-Year EBITDA Growth Rate falls into.
Optimi Health 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 36.40% mean?
Optimi Health (OPTHF) has a 3-Year EBITDA Growth Rate of 36.40% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Optimi Health and its competitors. This is 23% above median its historical median of 29.55. Over the past decade, Optimi Health's 3-Year EBITDA Growth Rate has ranged from 22.70 to 36.40. According to the industry distribution chart, Optimi Health ranks #135 out of 811 companies in the Drug Manufacturers industry, placing it in the top 16.6%.
Is Optimi Health's 3-Year EBITDA Growth Rate too high?
Optimi Health's current 3-Year EBITDA Growth Rate of 36.40% is 23% above median its 10-year median of 29.55. Over the past 10 years, this metric has ranged from a low of 22.70 to a high of 36.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Optimi Health's value of 36.40% is 313.6% above this industry median. Based on the distribution chart, Optimi Health ranks #135 out of 811 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Optimi Health has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Optimi Health's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Optimi Health ranks #135 out of 811 companies for 3-Year EBITDA Growth Rate. This places Optimi Health in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Optimi Health's value of 36.40% is 313.6% above this benchmark. Historically, Optimi Health's own 3-Year EBITDA Growth Rate has ranged from 22.70 to 36.40 over the past decade. While the company's 10-year median is 29.55 vs. the industry median of 8.80, Optimi Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Optimi Health's current 3-Year EBITDA Growth Rate of 36.40% is 313.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Optimi Health and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Optimi Health's current 3-Year EBITDA Growth Rate is 36.40%, which is 23% above median its own 10-year median of 29.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optimi Health stock overvalued right now?
Optimi Health (OPTHF) has a current 3-Year EBITDA Growth Rate of 36.40%. The stock's GF Value™ is $0.20, compared to a current price of $0.24 — trading 17.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 36.40%, which is 23% above median its 10-year median of 29.55 and 313.6% above the Drug Manufacturers industry median of 8.80. Optimi Health's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Optimi Health (OPTHF), the current 3-Year EBITDA Growth Rate is 36.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optimi Health (OPTHF) Overvalued in 2026?
Based on GuruFocus' analysis, Optimi Health stock appears to be overvalued.
The current stock price of $0.24 is trading 17.6% above its estimated GF Value™ of $0.20.
Key valuation signals for OPTHF:
3-Year EBITDA Growth Rate: 36.40% (23% above median its 10-year median of 29.55)
GF Value™: $0.20 vs. price of $0.24 (17.6% above fair value)
Industry Position: 313.6% above the Drug Manufacturers median (#135 of 811)
No single metric tells the full story. See the OPTHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
45GF Score
Get the complete analysis for OPTHF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPTHF has been successfully added to your 
